LRRC25 Is a Potential Biomarker for Predicting Immunotherapy Response in Patients with Gastric Cancer

Overview

Journal Dig Dis Sci

Specialty Gastroenterology

Date 2025 Feb 17

PMID 39961962

Authors

Zhensong Yang

Bin Yu

Jinchen Hu

Lixin Jiang

Mi Jian

Affiliations

Soon will be listed here.

Abstract

Background: Leucine-rich repeat containing 25 (LRRC25) is distinguishingly expressed in different tumor types, but the relationship with immune cell infiltration in gastric cancer stills unclear. We analyzed LRRC25 expression using pan-cancer data from The Cancer Genome Atlas and gene data from Gene Expression Omnibus. The clinical significance was further evaluated using gastric cancer tissues derived from clinical trials (no. NCT04208347).

Method: Through bioinformatics analysis of TCGA database and the UCSC Xena database, we found the correlation between LRRC15, gastric cancer, and immune cell infiltration. Further, multiplex immunohistochemistry/immunofluorescence (mIHC/IF), tissue microarray, and image acquisition and quantitative analysis confirmed our theory.

Results: It was discovered that LRRC25 was highly expressed in gastric cancer. Further analysis revealed that the expression of LRRC25 associated with gene sets implicated in immunity, including those in innate immunity, adaptive immunity, and chemokine signaling pathways. The result of (mIHC/IF) suggests a negative relevance between LRRC25 and response of anti-PD-1 treatment and reveals a trend of consistent change on LRRC25 + cells and CD16 expression. We also discovered that LRRC25 expression significantly associated with immune cell infiltration level. In particular, there is a relationship between LRRC25 and the phenotype and function of NK cells.

Conclusion: High LRRC25 expression contributes to immunosuppressive microenvironment by influencing chemokine axis in gastric cancer. LRRC25 may serve as a clinically useful biomarker for predicting neoadjuvant immunotherapeutic response in patients with gastric cancer. LRRC25 can affect the phenotype and function of NK cells.

References

Zheng R, Zhang S, Sun K, Chen R, Wang S, Li L . [Cancer statistics in China, 2016]. Zhonghua Zhong Liu Za Zhi. 2023; 45(3):212-220. DOI: 10.3760/cma.j.cn112152-20220922-00647. View

Smyth E, Nilsson M, Grabsch H, van Grieken N, Lordick F . Gastric cancer. Lancet. 2020; 396(10251):635-648. DOI: 10.1016/S0140-6736(20)31288-5. View

Fan B, Bu Z, Zhang J, Zong X, Ji X, Fu T . Phase II trial of prophylactic hyperthermic intraperitoneal chemotherapy in patients with locally advanced gastric cancer after curative surgery. BMC Cancer. 2021; 21(1):216. PMC: 7923597. DOI: 10.1186/s12885-021-07925-2. View

Wang F, Zhang X, Tang L, Wu Q, Cai M, Li Y . The Chinese Society of Clinical Oncology (CSCO): Clinical guidelines for the diagnosis and treatment of gastric cancer, 2023. Cancer Commun (Lond). 2023; 44(1):127-172. PMC: 10794017. DOI: 10.1002/cac2.12516. View

Wang F, Wei X, Wang F, Xu N, Shen L, Dai G . Safety, efficacy and tumor mutational burden as a biomarker of overall survival benefit in chemo-refractory gastric cancer treated with toripalimab, a PD-1 antibody in phase Ib/II clinical trial NCT02915432. Ann Oncol. 2019; 30(9):1479-1486. PMC: 6771223. DOI: 10.1093/annonc/mdz197. View

Janjigian Y, Kawazoe A, Yanez P, Li N, Lonardi S, Kolesnik O . The KEYNOTE-811 trial of dual PD-1 and HER2 blockade in HER2-positive gastric cancer. Nature. 2021; 600(7890):727-730. PMC: 8959470. DOI: 10.1038/s41586-021-04161-3. View

Ni X, Xing Y, Sun X, Suo J . The safety and efficacy of anti-PD-1/anti-PD-L1 antibody therapy in the treatment of previously treated, advanced gastric or gastro-oesophageal junction cancer: A meta-analysis of prospective clinical trials. Clin Res Hepatol Gastroenterol. 2019; 44(2):211-222. DOI: 10.1016/j.clinre.2019.05.007. View

Kim S, Cristescu R, Bass A, Kim K, Odegaard J, Kim K . Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018; 24(9):1449-1458. DOI: 10.1038/s41591-018-0101-z. View

Zheng Y, Wang Z, Yan C, Yan M, Hou Z, Zheng R . Protocol for a randomized controlled trial of perioperative S-1 plus oxaliplatin combined with apatinib and camrelizumab in patients with resectable, locally advanced gastric or gastroesophageal junction adenocarcinoma. Ann Transl Med. 2021; 8(24):1684. PMC: 7812167. DOI: 10.21037/atm-20-7802. View

10.

Salas-Benito D, Perez-Gracia J, Ponz-Sarvise M, Rodriguez-Ruiz M, Martinez-Forero I, Castanon E . Paradigms on Immunotherapy Combinations with Chemotherapy. Cancer Discov. 2021; 11(6):1353-1367. DOI: 10.1158/2159-8290.CD-20-1312. View

11.

Kang B, Camps J, Fan B, Jiang H, Ibrahim M, Hu X . Parallel single-cell and bulk transcriptome analyses reveal key features of the gastric tumor microenvironment. Genome Biol. 2022; 23(1):265. PMC: 9773611. DOI: 10.1186/s13059-022-02828-2. View

12.

Kono K, Nakajima S, Mimura K . Current status of immune checkpoint inhibitors for gastric cancer. Gastric Cancer. 2020; 23(4):565-578. DOI: 10.1007/s10120-020-01090-4. View

13.

Zhang Q, Wang J, Fan S, Wang L, Cao L, Tang K . Expression and functional characterization of LRRC4, a novel brain-specific member of the LRR superfamily. FEBS Lett. 2005; 579(17):3674-82. DOI: 10.1016/j.febslet.2005.05.058. View

14.

Wang Y, Peng Y, Zhou Y, Zhou Y, Zhong H . The clinical value of LRRC3B gene expression and promoter hypermethylation in breast carcinomas. Cell Biochem Biophys. 2014; 70(2):1035-41. DOI: 10.1007/s12013-014-0018-1. View

15.

Takahashi N, Takahashi Y, Putnam F . Periodicity of leucine and tandem repetition of a 24-amino acid segment in the primary structure of leucine-rich alpha 2-glycoprotein of human serum. Proc Natl Acad Sci U S A. 1985; 82(7):1906-10. PMC: 397442. DOI: 10.1073/pnas.82.7.1906. View

16.

Xian H, Yang S, Jin S, Zhang Y, Cui J . LRRC59 modulates type I interferon signaling by restraining the SQSTM1/p62-mediated autophagic degradation of pattern recognition receptor DDX58/RIG-I. Autophagy. 2019; 16(3):408-418. PMC: 6999607. DOI: 10.1080/15548627.2019.1615303. View

17.

Ren F, Zhao Q, Zhao M, Zhu S, Liu B, Bukhari I . Immune infiltration profiling in gastric cancer and their clinical implications. Cancer Sci. 2021; 112(9):3569-3584. PMC: 8409427. DOI: 10.1111/cas.15057. View

18.

Subramanian A, Tamayo P, Mootha V, Mukherjee S, Ebert B, Gillette M . Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles. Proc Natl Acad Sci U S A. 2005; 102(43):15545-50. PMC: 1239896. DOI: 10.1073/pnas.0506580102. View

19.

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

20.

Ru B, Wong C, Tong Y, Zhong J, Zhong S, Wu W . TISIDB: an integrated repository portal for tumor-immune system interactions. Bioinformatics. 2019; 35(20):4200-4202. DOI: 10.1093/bioinformatics/btz210. View